MX2015013000A - Metodos de mantenimiento y mejora de la funcion muscular. - Google Patents

Metodos de mantenimiento y mejora de la funcion muscular.

Info

Publication number
MX2015013000A
MX2015013000A MX2015013000A MX2015013000A MX2015013000A MX 2015013000 A MX2015013000 A MX 2015013000A MX 2015013000 A MX2015013000 A MX 2015013000A MX 2015013000 A MX2015013000 A MX 2015013000A MX 2015013000 A MX2015013000 A MX 2015013000A
Authority
MX
Mexico
Prior art keywords
muscle function
methods
maintaining
improving muscle
egcg
Prior art date
Application number
MX2015013000A
Other languages
English (en)
Inventor
Suzette Pereira
Sean Garvey
Neile Edens
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2015013000A publication Critical patent/MX2015013000A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42—Preservation of non-alcoholic beverages
    • A23L2/50—Preservation of non-alcoholic beverages by irradiation or electric treatment without heating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se proporcionan métodos para disminuir la pérdida de función muscular y mejorar la función muscular en un sujeto. Los métodos utilizan una cantidad eficaz de epigalocatequina-3-galato (EGCg) para aumentar el nivel del factor de crecimiento endotelial vascular A (VEGF), para disminuir los niveles de miostatina, o ambos, y de ese modo disminuir la pérdida de la función muscular o mejorar la función muscular. El EGCg se puede proporcionar como parte de una composición nutricional.
MX2015013000A 2013-03-15 2014-03-14 Metodos de mantenimiento y mejora de la funcion muscular. MX2015013000A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792489P 2013-03-15 2013-03-15
US201361823832P 2013-05-15 2013-05-15
PCT/US2014/028879 WO2014144458A1 (en) 2013-03-15 2014-03-14 Methods of maintaining and improving muscle function

Publications (1)

Publication Number Publication Date
MX2015013000A true MX2015013000A (es) 2015-12-01

Family

ID=50555279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013000A MX2015013000A (es) 2013-03-15 2014-03-14 Metodos de mantenimiento y mejora de la funcion muscular.

Country Status (11)

Country Link
US (1) US9844531B2 (es)
EP (1) EP2986158A1 (es)
JP (1) JP2016517438A (es)
CN (1) CN105431057A (es)
BR (1) BR112015023031A2 (es)
CA (1) CA2903565A1 (es)
HK (1) HK1221611A1 (es)
MX (1) MX2015013000A (es)
PH (1) PH12015502167A1 (es)
SG (1) SG11201507135XA (es)
WO (1) WO2014144458A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160361291A1 (en) * 2013-12-18 2016-12-15 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
WO2016044272A1 (en) * 2014-09-16 2016-03-24 Abbott Laboratories Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract
US20190126075A1 (en) * 2015-09-30 2019-05-02 Kyodo Milk Industry Co., Ltd. Food and drink product containing poorly digestible compound and colonic-hydrogen-gas producing agent
MX2018008589A (es) * 2016-01-13 2018-11-09 Metabolic Tech Inc COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA ESTABILIDAD DE ARTICULACION.
EP3463321A1 (en) * 2016-05-27 2019-04-10 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
CA3041520A1 (en) * 2016-10-21 2018-04-26 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and probiotics
WO2018183251A1 (en) 2017-03-31 2018-10-04 Abbott Laboratories Liquid nutritional compositions containing oxidizable fish oil, rosmarinic acid and ferric iron
US20200163370A1 (en) 2017-08-03 2020-05-28 Abbott Laboratories Liquid nutritional compositions including green tea extract and iron
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
KR102281263B1 (ko) * 2019-03-12 2021-07-26 주식회사 비티씨 갈릭산, 에피카테킨(ec), 및 에피갈로카테킨(egc)의 함량이 증가된 카테킨 효소처리물 및 이의 제조방법
US20210228657A1 (en) * 2019-04-23 2021-07-29 Glac Biotech Co., Ltd. Food composition and pharmaceutical composition used for increasing exercise performance and ameliorating fatigue
CA3140735A1 (en) * 2019-07-05 2021-01-14 Societe Des Produits Nestle S.A. Compositions and methods using trigonelline and vitamins for preventing or treating conditions or disorders in skeletal muscle
US20220312818A1 (en) * 2019-07-25 2022-10-06 Korea University Research And Business Foundation Preparation method for two-spotted cricket powder or extract thereof, food composition comprising same, and uses of same
CN111000233A (zh) * 2019-11-28 2020-04-14 湖南农业大学 Ecg作为健肌功能成分的应用
CN110839890B (zh) * 2019-12-03 2022-06-21 湖南农业大学 一种茶黄素健肌的膳食营养补充剂的及其制备方法
WO2021072450A2 (en) * 2020-03-10 2021-04-15 The Regents Of The University Of California Novel nutrients to enhance load-induced muscle hypertrophy
KR20220015769A (ko) * 2020-07-31 2022-02-08 고려대학교 산학협력단 그릴루스 비마쿨라투스를 유효성분으로 포함하는 근위축증의 예방, 개선 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219871T3 (es) 1997-02-21 2004-12-01 Abbott Laboratories Procedimiento y composiciones que sirven para limitar la frecuencia de la enterocolitis necrotizante del recien nacido.
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
IL162505A0 (en) 2001-12-19 2005-11-20 The Quigley Corp Method for treatment of peripheral neural and vascular ailments
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
JP2006131512A (ja) 2004-11-02 2006-05-25 Pharma Foods International Co Ltd アディポネクチン分泌促進組成物および該組成物を含有する飲食品
FR2882896B1 (fr) 2005-03-14 2007-05-04 Larena Sa Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US20090163579A1 (en) 2005-10-14 2009-06-25 Daniel Raederstorff Novel use of nutraceutical compositions
ATE537819T1 (de) * 2005-10-14 2012-01-15 Dsm Ip Assets Bv Nutrazeutische zusammensetzungen zur behandlung von muskelschwund
WO2007053929A1 (en) * 2005-11-08 2007-05-18 Accelis Formulations Ltd. Diet supplement and method for weight-loss
KR101558231B1 (ko) 2006-05-01 2015-10-08 (주)아모레퍼시픽 (-)카테친을 함유하는 아디포넥틴 발현 증강제
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
KR20090037404A (ko) 2006-07-05 2009-04-15 카오카부시키가이샤 근력 향상제
JP2008013473A (ja) * 2006-07-05 2008-01-24 Kao Corp 筋機能低下抑制剤
US8962678B2 (en) 2006-07-05 2015-02-24 Kao Corporation Senescence inhibitor
EP1961310A1 (en) * 2007-02-01 2008-08-27 DSMIP Assets B.V. Novel use of (-) -epigallocatechin gallate
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
JP2009120491A (ja) 2007-11-12 2009-06-04 Tsujido Kagaku Kk アディポネクチン産生促進剤
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
AU2010233073B2 (en) 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
US20100303937A1 (en) 2009-06-01 2010-12-02 Michael Farber Novel composition to increase testosterone levels
US20120148685A1 (en) 2009-06-10 2012-06-14 Engergy4Life AG Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
AU2010274125B2 (en) 2009-07-20 2015-11-05 Société des Produits Nestlé S.A. Methods of attenuating the loss of functional status
CA2787002A1 (en) 2010-01-25 2011-07-28 Concept Medical Research Private Limited A method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent
EP2827856A4 (en) * 2012-03-23 2016-03-09 Cardero Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
WO2014028607A1 (en) 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
SG11201502649WA (en) 2012-10-04 2015-05-28 Abbott Lab Methods for enhancing the effect of egcg on mitigating skeletal muscle loss

Also Published As

Publication number Publication date
HK1221611A1 (zh) 2017-06-09
JP2016517438A (ja) 2016-06-16
US9844531B2 (en) 2017-12-19
EP2986158A1 (en) 2016-02-24
BR112015023031A2 (pt) 2017-07-18
PH12015502167A1 (en) 2016-01-25
CN105431057A (zh) 2016-03-23
CA2903565A1 (en) 2014-09-18
US20160038457A1 (en) 2016-02-11
WO2014144458A1 (en) 2014-09-18
SG11201507135XA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
PH12015502167A1 (en) Methods of maintaining and improving muscle function
PH12019550096A1 (en) Beta-casein a2 and prevention of inflammation of the bowel
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
PH12015502319A1 (en) Methods for enhancing aged muscle regeneration
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
NZ713325A (en) Supplemented fish feed
MX2021016114A (es) Formulaciones para estabilizar la humedad en alimentos musculares.
EA032501B9 (ru) Способы и композиции для содействия заживлению острой раны и хронической раны
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
AR093632A1 (es) Tratamiento de cafe soluble
EP3010499A4 (en) Compositions comprising at least one polymethoxyflavone, flavonoid, liminoid, and/or tocotrienol useful in combination therapies for treating diabetes
PL2820953T3 (pl) Szczep Glomus iranicum var. tenuihypharum var. nov. i jego zastosowanie jako biostymulatora
PH12019550209A1 (en) A nutritional composition for use to enhance attention and/or reduce impulsivity
IN2014MN01968A (es)
MX362111B (es) Un metodo para mejorar la funcion hepatica.
MX2017014971A (es) Composiciones de sal mejoradas y metodo de preparacion de las mismas.
PL2821478T3 (pl) Szczep Glomus iranicum var. tenuihypharum var. nov. i jego zastosowanie jako bio-nematocyd
Paya Future of Religion in Modern World
MX2016005816A (es) Sistema conservador.
MX345908B (es) Sistema de energía comestible.
MX2015008947A (es) Nuevas composiciones antifungicas.
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе